Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 231

1.

Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.

Georgiadis A, Durham JN, Keefer LA, Bartlett BR, Zielonka M, Murphy D, White JR, Lu S, Verner EL, Ruan F, Riley D, Anders RA, Gedvilaite E, Angiuoli S, Jones S, Velculescu VE, Le DT, Diaz LA Jr, Sausen M.

Clin Cancer Res. 2019 Sep 10. doi: 10.1158/1078-0432.CCR-19-1372. [Epub ahead of print]

PMID:
31506389
2.

Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.

Llosa NJ, Luber B, Siegel N, Awan AH, Oke T, Zhu Q, Bartlett BR, Aulakh LK, Thompson ED, Jaffee EM, Durham JN, Sears CL, Le DT, Diaz LA Jr, Pardoll DM, Wang H, Housseau F, Anders RA.

Cancer Immunol Res. 2019 Aug 22. doi: 10.1158/2326-6066.CIR-18-0927. [Epub ahead of print]

PMID:
31439614
3.

"Hey CIRI, What's My Prognosis?"

Wan JCM, White JR, Diaz LA Jr.

Cell. 2019 Jul 25;178(3):518-520. doi: 10.1016/j.cell.2019.07.005.

PMID:
31348884
4.

Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.

Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA Jr, Schultz N, Janjigian YY, Ku GY.

Clin Cancer Res. 2019 Jul 23. doi: 10.1158/1078-0432.CCR-18-3603. [Epub ahead of print]

PMID:
31337644
5.

Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a "hit-and-run" mechanism.

Lin L, Moran TP, Peng B, Yang J, Culton DA, Che H, Jiang S, Liu Z, Geng S, Zhang Y, Diaz LA, Qian Y.

J Allergy Clin Immunol. 2019 Sep;144(3):720-728.e4. doi: 10.1016/j.jaci.2019.04.020. Epub 2019 May 6.

PMID:
31071340
6.

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates.

Wang Y, Johnson DB, Lu S, Diaz LA Jr, Xu Y, Balko JM.

J Immunother Cancer. 2019 May 7;7(1):123. doi: 10.1186/s40425-019-0584-2.

7.

Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.

Llosa NJ, Luber B, Tam AJ, Smith KN, Siegel N, Awan AH, Fan H, Oke T, Zhang J, Domingue J, Engle EL, Roberts CA, Bartlett BR, Aulakh LK, Thompson ED, Taube JM, Durham JN, Sears CL, Le DT, Diaz LA, Pardoll DM, Wang H, Anders RA, Housseau F.

Clin Cancer Res. 2019 Sep 1;25(17):5250-5259. doi: 10.1158/1078-0432.CCR-19-0114. Epub 2019 May 6.

PMID:
31061070
8.

Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.

Mandal R, Samstein RM, Lee KW, Havel JJ, Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, Ramaswamy AT, Durham JN, Bartlett B, Ma X, Srivastava R, Middha S, Zehir A, Hechtman JF, Morris LG, Weinhold N, Riaz N, Le DT, Diaz LA Jr, Chan TA.

Science. 2019 May 3;364(6439):485-491. doi: 10.1126/science.aau0447.

9.

Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions.: A collaboration between the Chilean Liver Transplant Programs, the Public Health Institute and the National Transplant Coordinator.

Díaz LA, Norero B, Lara B, Robles C, Elgueta S, Humeres R, Poniachik J, Silva G, Wolff R, Innocenti F, Rojas JL, Zapata R, Hunter B, Álvarez S, Cancino A, Ibarra J, Rius M, González S, Calabrán L, Pérez RM.

Ann Hepatol. 2019 Mar - Apr;18(2):325-330. doi: 10.1016/j.aohep.2018.11.001. Epub 2019 Apr 12.

10.

Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.

Middha S, Yaeger R, Shia J, Stadler ZK, King S, Guercio S, Paroder V, Bates DDB, Rana S, Diaz LA Jr, Saltz L, Segal N, Ladanyi M, Zehir A, Hechtman JF.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00321. Epub 2019 Mar 4.

11.

Immunotherapy in colorectal cancer: rationale, challenges and potential.

Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr.

Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375. doi: 10.1038/s41575-019-0126-x. Review.

PMID:
30886395
12.

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Mar 6;7(1):63. doi: 10.1186/s40425-019-0547-7.

13.

Childhood pemphigus foliaceus presenting as a polycyclic eruption: Case report and review of the literature.

Evans MS, Culton DA, Diaz LA, Googe PB, Morrell DS.

Pediatr Dermatol. 2019 Mar;36(2):236-241. doi: 10.1111/pde.13750. Epub 2019 Feb 14. Review.

PMID:
30762246
14.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

15.

Association of pre-eclampsia risk with maternal levels of folate, homocysteine and vitamin B12 in Colombia: A case-control study.

Serrano NC, Quintero-Lesmes DC, Becerra-Bayona S, Guio E, Beltran M, Paez MC, Ortiz R, Saldarriaga W, Diaz LA, Monterrosa Á, Miranda J, Mesa CM, Sanin JE, Monsalve G, Dudbridge F, Hingorani AD, Casas JP.

PLoS One. 2018 Dec 6;13(12):e0208137. doi: 10.1371/journal.pone.0208137. eCollection 2018.

16.

Acquired resistance to immunotherapy in MMR-D pancreatic cancer.

Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, Diaz LA Jr, O'Reilly EM.

J Immunother Cancer. 2018 Nov 20;6(1):127. doi: 10.1186/s40425-018-0448-1.

17.

Correction: Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, Ptak J, Dobbyn L, Papoli M, Kinde I, Afsari B, Tregnago AC, Bezerra SM, VandenBussche C, Fujita K, Ertoy D, Cunha IW, Yu L, Bivalacqua TJ, Grollman AP, Diaz LA, Karchin R, Danilova L, Huang CY, Shun CT, Turesky RJ, Yun BH, Rosenquist TA, Pu YS, Hruban RH, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Dickman KG, Netto GJ.

Elife. 2018 Nov 12;7. pii: e43237. doi: 10.7554/eLife.43237.

18.

Managing Clonal Hematopoiesis in Patients With Solid Tumors.

Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA Jr, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E.

J Clin Oncol. 2019 Jan 1;37(1):7-11. doi: 10.1200/JCO.18.00331. Epub 2018 Nov 7. No abstract available.

PMID:
30403571
19.

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O'Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK.

J Clin Oncol. 2019 Feb 1;37(4):286-295. doi: 10.1200/JCO.18.00283. Epub 2018 Oct 30. Erratum in: J Clin Oncol. 2019 Apr 10;37(11):942.

20.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

Supplemental Content

Loading ...
Support Center